Cancer cell plasma membrane and surface macromolecules

The cancer cell plasma membrane and its associated surface macromolecules represent the primary interface between a tumor cell and its microenvironment, serving as a critical hub for signaling and nutrient exchange (PMID: 30108304). This complex structure consists of a lipid bilayer embedded with diverse proteins—such as receptors, transporters, and enzymes—and is often covered by a dense layer of carbohydrates known as the glycocalyx (PMID: 28653671). These surface components are frequently altered in malignancy, driving uncontrolled proliferation, metastasis, and immune evasion (PMID: 31515460). In oncology, the cell surface is the most common site for therapeutic intervention, as it is readily accessible to circulating drugs like monoclonal antibodies and antibody-drug conjugates. While specific macromolecules (e.g., HER2, EGFR) are the primary focus of targeted therapies, the general membrane environment itself is also a subject of research for membrane-disrupting agents. However, because many of these components are also present on healthy cells, achieving high selectivity remains a significant therapeutic challenge (PMID: 25817491).

Other names

Cancer cell surfaceTumor cell membraneNeoplastic cell surfaceCancer cell glycocalyxTumor cell plasma membrane

Drugs targeting this compartment act through diverse mechanisms, including the binding of monoclonal antibodies to specific surface antigens to induce ADCC or inhibit signaling, the disruption of lipid bilayer integrity by membrane-active peptides or alkylphosphocholines, and the inhibition of membrane-bound transporters and enzymes to disrupt cellular homeostasis (PMID: 30108304, PMID: 31515460).